Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Accounts Payables (2021 - 2025)

Historic Accounts Payables for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $5.3 million.

  • Amylyx Pharmaceuticals' Accounts Payables rose 25904.51% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 25904.51%. This contributed to the annual value of $2.9 million for FY2024, which is 8667.78% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Accounts Payables stood at $5.3 million for Q3 2025, which was up 25904.51% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Accounts Payables registered a high of $24.7 million during Q2 2023, and its lowest value of $1.5 million during Q3 2024.
  • Moreover, its 5-year median value for Accounts Payables was $6.3 million (2022), whereas its average is $9.0 million.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Accounts Payables tumbled by 8667.78% in 2024, and later skyrocketed by 25904.51% in 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Accounts Payables (Quarter) stood at $4.4 million in 2021, then soared by 43.12% to $6.3 million in 2022, then soared by 252.58% to $22.1 million in 2023, then plummeted by 86.68% to $2.9 million in 2024, then skyrocketed by 81.66% to $5.3 million in 2025.
  • Its Accounts Payables stands at $5.3 million for Q3 2025, versus $3.3 million for Q2 2025 and $4.8 million for Q1 2025.